NCT04497376 (PROMPT-AF) is a NA clinical trial of upgraded '2C3L' in Persistent Atrial Fibrillation, sponsored by Beijing Anzhen Hospital.

Who is sponsoring NCT04497376?

NCT04497376 is sponsored by Beijing Anzhen Hospital.

What drugs are being tested in NCT04497376?

Interventions in NCT04497376: upgraded '2C3L', pulmonary vein antral isolation.

What condition does NCT04497376 study?

NCT04497376 studies Persistent Atrial Fibrillation, Catheter Ablation.

Is NCT04497376 still recruiting?

NCT04497376 is currently completed. Last updated 19 July 2024.

Last reviewed 2024-07-19 · How we verify

NCT04497376: PROMPT-AF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation

Completed NA Last updated 19 July 2024

What this trial tests

NA trial testing upgraded '2C3L' in Persistent Atrial Fibrillation in 498 participants. Completed in 18 July 2024.

Timeline

27 August 2021

Primary endpoint
18 July 2024

18 July 2024

Quick facts

Lead sponsor	Beijing Anzhen Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	498
Start date	27 August 2021
Primary completion	18 July 2024
Estimated completion	18 July 2024
Sites	12 locations across China

Drugs / interventions tested

upgraded '2C3L'
pulmonary vein antral isolation

Conditions studied

Persistent Atrial Fibrillation — all drugs for Persistent Atrial Fibrillation →
Catheter Ablation — all drugs for Catheter Ablation →

Sponsor

Beijing Anzhen Hospital

Who can join

Adults 18 to 80, any sex, with Persistent Atrial Fibrillation or Catheter Ablation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Catheter ablation has emerged as an important treatment option for patients with symptomatic atrial fibrillation (AF). Pulmonary vein antral isolation (PVI) is now considered the cornerstone technique of AF ablation and has shown promise in treating paroxysmal atrial fibrillation (PAF). However, there is no unique strategy for ablation of persistent AF (PeAF), whether PVI alone is sufficient to prevent patients from recurrence remains controversial. The PROMPT-AF study is a prospective, multicenter, randomized trial involving a blinded assessment of outcomes, which is designed to compare arrhythmia-free survival between PVI and an ablation strategy termed upgraded '2C3L' for ablation of PeAF.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF: The PROMPT-AF Randomized Clinical Trial.
Sang C, Liu Q, Lai Y, Xia S, et al · · 2025 · cited 57× · PMID 39556379 · DOI 10.1001/jama.2024.24438
Clinical Trials on Atrial Fibrillation in Asia: Where Are We Now.
Kong X, Yang Z, Ma C. · · 2025 · PMID 41344742 · DOI 10.1016/j.jacasi.2025.09.005

Verify or expand the search:

Other recruiting trials for Persistent Atrial Fibrillation

Currently open trials in the same condition.

NCT07298473 — Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sp · NA · recruiting
NCT07535268 — REPRESENT-PF Registry · recruiting
NCT07508618 — Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule · Phase 4 · recruiting
NCT07116525 — A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter · NA · recruiting
NCT07106970 — PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II) · NA · recruiting

Other Beijing Anzhen Hospital trials

Trials by the same sponsor.

NCT07521488 — LLM-Based Intelligent Health Management Assistant in Life-Cycle Health Management of Cardiac Surgery Patients · NA · not yet recruiting
NCT07470814 — Multidisciplinary Collaborative Care System for Acute Myocardial Infarction Complicated With Cardiogenic Shock · not yet recruiting
NCT07444372 — Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation · NA · not yet recruiting
NCT07256197 — PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis · Phase 3 · not yet recruiting
NCT07485101 — Glycemic Targets During CPB in Elderly Diabetes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04497376 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Anzhen Hospital
Last refreshed: 19 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04497376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing